Prices are updated after-hours

Professional, Scientific, and Technical Services 2022 - 03 - 31

Impel NeuroPharma Inc.

IMPL 4 | $0.2411 -77.19% 860K

(0.0% 1d) (0.0% 1m) (-76.5% 1y) (0.0% 2d) (10.1% 3d) (0.0% 7d) (-28.63% volume)
Earnings Calendar: 2024-03-22
Market Cap: $ 5,762,297
https://impelnp.com
Sec Filling | Patents | n/a employees

(US) Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

parkinson treatment

add to watch list Paper trade email alert is off

Elvictor Group, Inc.

ELVG | $0.0125 225.6% 50K

Professional, Scientific, and T...

(0.0% 1d) (-0.8% 1m) (-68.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (0.0% volume)
Earnings Calendar:
Market Cap: $ 5,180,609

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

Kallo Inc.

KALO | $0.0003 24900.0% 100

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-97.98% volume)
Earnings Calendar:
Market Cap: $ 1,906,929

Sec Filling | Patents | 4 employees

kallo offers a comprehensive healthcare delivery program dedicated to providing the most technologically advanced, innovative healthcare solution that is customized to the requirements of each country, including effective infectious disease management and customized education and training programs. the company's technology suite transforms healthcare delivery via rural healthcare, disease management, clinical globalization and ehealth solutions. for more information on kallo and ongoing business developments, please visit us at www.kalloinc.ca

education

add to watch list Paper trade email alert is off

Hubilu Venture Corp

HBUV | $0.06 0% 100

Professional, Scientific, and T...

(0.0% 1m) (-93.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (0.0% volume)
Earnings Calendar:
Market Cap: $ 1,574,228

Sec Filling | Patents | 3 employees

hubilu venture corporation is a u.s. corporation specializing in real estate consulting services and property acquisition in the los angeles area.

add to watch list Paper trade email alert is off

U.S. Stem Cell, Inc.

USRM | $0.0001 1300.0% 290K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-96.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (4815.12% volume)
Earnings Calendar:
Market Cap: $ 66,151
http://us-stemcell.com/
Sec Filling | Patents | 11 employees

(United States) u.s. stem cell, inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. the company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product adipocell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. in the past 20 years, to the company’s knowledge, u.s. stem cell, inc. has completed more clinical treatments than any other regenerative care provider in the world. with more than 700 physicians trained and certified with the company, u.s. stem cell, inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

t-cell

add to watch list Paper trade email alert is off

eWELLNESS HEALTHCARE Corp

EWLL | $0.0001 100.0% 100

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-99.9% volume)
Earnings Calendar:
Market Cap: $ 1,847,824

Sec Filling | Patents | 9 employees

(US)

add to watch list Paper trade email alert is off

MDwerks, Inc.

MDWK | $0.21 -60.0% 2.5K

Professional, Scientific, and T...

(0.0% 1d) (-4.5% 1m) (600.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (150.0% volume)
Earnings Calendar:
Market Cap: $ 26,773,219

Sec Filling | Patents | 7 employees

learn about working at mdwerks. join linkedin today for free. see who you know at mdwerks, leverage your professional network, and get hired.

add to watch list Paper trade email alert is off

Vivakor, Inc.

VIVK | $1.1 12.25% 10.91% 350K

Professional, Scientific, and T...

(0.0% 1d) (1.4% 1m) (-17.9% 1y) (0.0% 2d) (0.0% 3d) (-3.3% 7d) (-17.23% volume)
Earnings Calendar:
Market Cap: $ 30,481,278

Sec Filling | Patents | 25 employees

vivakor inc is a company based out of 2590 holiday rd ste 100, coralville, iowa, united states.

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-8.0% 1m) (-79.0% 1y) (0.0% 2d) (0.0% 3d) (12.2% 7d) (-81.77% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Unicycive Therapeutics Inc

UNCY | $1.08 -0.92% -0.93% 230K

Professional, Scientific, and T...

(0.0% 1d) (-23.2% 1m) (-32.3% 1y) (0.0% 2d) (-6.0% 3d) (-4.4% 7d) (550.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,536,951
https://unicycive.com
Sec Filling | Patents | 2021 employees

Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

treatment kidney

add to watch list Paper trade email alert is off

TransCode Therapeutics Inc

RNAZ | $0.49 -2.39% -2.45% 110K

Professional, Scientific, and T...

(0.0% 1d) (-28.6% 1m) (-92.9% 1y) (0.0% 2d) (0.0% 3d) (-6.8% 7d) (31.17% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 2,845,946
https://www.transcodetherapeutics.com
Sec Filling | Patents | 2021 employees

TransCode Therapeutics is an emerging RNA oncology company created to realize its belief that cancer can be defeated through the intelligent design of RNA therapeutics. This belief is based on a new approach to address what TransCode believes has been the most intractable challenge in RNA therapeutics: delivering an oligonucleotide to its target before the body’s immune system can attack and dismantle it. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which TransCode believes has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. TransCode anticipates submitting an IND, in the second half of 2021 to support initiation of a Phase 0 clinical study with TTX-MC138.

cancer pancreatic glioblastoma

add to watch list Paper trade email alert is off

OMNIQ Corp

OMQS | $0.4533 -15.65% -18.55% 340K

Professional, Scientific, and T...

(0.0% 1d) (13.9% 1m) (-85.9% 1y) (0.0% 2d) (2.0% 3d) (-10.1% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,845,873
https://www.omniq.com
Sec Filling | Patents | 61 employees

OMNIQ Corp. provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real-time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments. OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad. The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023.

security

add to watch list Paper trade email alert is off

IonQ Inc

IONQ 4 | $7.09 -3.8% -0.42% 4.8M

Professional, Scientific, and T...

(0.0% 1d) (-24.0% 1m) (19.3% 1y) (0.0% 2d) (0.0% 3d) (-3.3% 7d) (-25.41% volume)
Earnings Calendar:
Market Cap: $ 1,476,347,290
https://ionq.com
Sec Filling | Patents | n/a employees

IonQ, Inc. is a leader in quantum computing, with a proven track record of innovation and deployment. IonQ’s next-generation quantum computer is the world’s most powerful trapped-ion quantum computer, and IonQ has defined what it believes is the best path forward to scale. IonQ is the only company with its quantum systems available through the cloud on Amazon Braket, Microsoft Azure, and Google Cloud, as well as through direct API access. IonQ was founded in 2015 by Christopher Monroe and Jungsang Kim based on 25 years of pioneering research.

computational

add to watch list Paper trade email alert is off

iCoreConnect Inc.

ICCT | $1.175 -1.26% -1.28% 29K

Professional, Scientific, and T...

(0.0% 1d) (-7.0% 1m) (941.7% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (-63.12% volume)
Earnings Calendar:
Market Cap: $ 10,517,980

Sec Filling | Patents | 25 employees

icoreconnect creates software that allows anyone to share information at the highest security levels in the country, backed by highly-engaged customer support. the company provides secure communications for high-compliance industries including healthcare, finance and legal. icoreconnect’s software allows organizations and individuals to freely and easily exchange information with 2048-bit encryption, and in full compliance of current federal laws.

communication

add to watch list Paper trade email alert is off

Integrated Cannabis Solutions, Inc.

IGPK | $0.011 123.26% 23M

Professional, Scientific, and T...

(0.0% 1d) (122.2% 1m) (614.3% 1y) (0.0% 2d) (0.0% 3d) (13.6% 7d) (375.22% volume)
Earnings Calendar:
Market Cap: $ 44,019,988

Sec Filling | Patents | 1 employees

(US)

add to watch list Paper trade email alert is off

Nevada Canyon Gold Corp.

NGLD | $3.26 -35.02% 6.6K

Professional, Scientific, and T...

(0.0% 1d) (-8.2% 1m) (117.3% 1y) (0.0% 2d) (6.5% 3d) (-20.5% 7d) (-80.24% volume)
Earnings Calendar:
Market Cap: $ 82,690,718

Sec Filling | Patents | 1 employees

add to watch list Paper trade email alert is off

Starco Brands, Inc.

STCB 4 | $0.1397 311.77% 210K

Professional, Scientific, and T...

(0.0% 1d) (7.7% 1m) (0.0% 1y) (0.0% 2d) (7.7% 3d) (12.6% 7d) (50.97% volume)
Earnings Calendar:
Market Cap: $ 68,042,919

Sec Filling | Patents | 1 employees

starco brands (sb) is a company who’s unwavering mission is to create behavior-changing brands and products. the commitment to change the way we approach everyday activities is innate in our corporate dna. sb is an invention factory. sb's core competency is inventing products, marketing brands, building trends, pushing awareness, penetrating social media and driving traffic with cutting edge pull-through strategies. the marketing brain trust of sb is a best-in-class, globally proven team that is sought after to manage the largest brands in the world. this team is like no other, and its client experience includes apple, target, uber, volkswagen, behr paint, ralph loren and many other iconic brands. welcome to a 21st century consumer products powerhouse.

add to watch list Paper trade email alert is off

Cell Source, Inc.

CLCS | $0.398 15.25% 2.1K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (132566.7% 1y) (0.0% 2d) (0.0% 3d) (0.1% 7d) (-83.4% volume)
Earnings Calendar:
Market Cap: $ 16,325,701

Sec Filling | Patents | 1 employees

marrow cell source , has been started with the aim to cater to patients who required a matched bone marrow sample. indian gene pool requires a bone marrow registry

t-cell

add to watch list Paper trade email alert is off

Rennova Health, Inc.

RNVA | $0.0001 0.0% 140M

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-99.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-23.24% volume)
Earnings Calendar:
Market Cap: $ 4,055,132
https://www.rennovahealth.com/
Sec Filling | Patents | 78 employees

(US) we put the needs of healthcare providers at the center of everything we do. we understand the unprecedented challenges faced by providers today. we have made it our mission to create single-source solutions that help you navigate today’s turbulent regulatory, medical and market environments while protecting your patients, your employees and your profitability. our unified approach is driving new ideas rennova health is reimagining the traditional channels of healthcare services with an expansive suite of diverse products and brands. these interoperable solutions work in unison to drive better treatment outcomes, more cost-effective patient care, and optimized revenue streams. we support each of our solutions with unprecedented service excellence, while continuing to build on the best medical science and technologies available. we also maintain the highest standards of corporate transparency, fiduciary responsibility, accountability, and regulatory compliance. rennova health encompasses

profitable

add to watch list Paper trade email alert is off

ACORN ENERGY, INC.

ACFN | $7.0 -95.92% 190

Professional, Scientific, and T...

(0.0% 1d) (-9.9% 1m) (1902.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (260.61% volume)
Earnings Calendar:
Market Cap: $ 17,411,149

Sec Filling | Patents | 23 employees

acorn energy, inc. is a holding company whose four portfolio companies help their customers achieve greater productivity, reliability, security, and efficiency—factors which can lead to greater profitability. us seismic systems supplies fiber optic sensing solutions to increase oil/gas production and lower costs. gridsense provides monitoring for all critical points along the electricity delivery system. omnimetrix remotely monitors emergency back-up power generation systems to increase their reliability. dsit provides security solutions from underwater threats to naval and marine based energy assets. for more information visit: http://www.acornenergy.com. this profile may include forward-looking statements, which are subject to risks and uncertainties. there is no assurance that acorn energy, inc. or its operating companies will continue to grow their respective businesses, or that any of them will meet the expectations or execute the initiatives described or referred to above. a comp

profitable eletrical energy

add to watch list Paper trade email alert is off